Navigation Links
Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011
Date:8/9/2011

SAN DIEGO, Aug. 9, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today reported a summary of recent Company highlights and financial results for the second quarter and six months ended June 30, 2011.

"I am very pleased with the progress we've made in terms of product revenues and partnership negotiations in the first half of the year," said James E. Levine, President and Chief Executive Officer at Verenium. "In the second quarter we saw significant growth and diversification of product revenues through our Grain and Oilseed Processing products.  In addition, we entered into an important collaboration with Novus International Inc. to develop multiple products for the animal health and nutrition market, demonstrating the value of Verenium's product development capabilities in the large and growing global industrial enzymes market."

Company HighlightsSince the beginning of 2011, Verenium has made significant progress on both operational and financial fronts.  Recent accomplishments include:

Operational/Industry Performance:

Animal Health and Nutrition

  • Announced a strategic collaboration with Novus International Inc. to jointly develop and commercialize a suite of new animal health and nutrition enzyme products from Verenium's late-stage product pipeline.

  • Grain Processing

  • Grew 2011 year-to-date revenues from the Company's grain processing enzymes, including Fuelzyme® alpha-amylase, Deltazym® GA L-E5 glucoamylase, Veretase® alpha-amylase and Xylathin™ xylanase, by 35% over the same period in 2010; and
  • Grain processing has grown to represent 31% of 2011 year-to-date product revenues from 25% during the same period in 2010.

  • Oilseed Processing

  • Achieved a 100% increase in 2011 year-to-date revenue from Purifine® PLC over the same period in 2010 due to higher utilization at higher prices to our existing customers.

  • Corporate/Financial:

  • Increased total product revenue by 11% to $27.5 million for the first half of 2011, compared to $24.9 million for the same period in 2010;
  • Increased 2011 year-to-date product revenue from Grain and Oilseed Processing product lines as a percentage of product revenue to approximately 40% from approximately 30% in the same period in 2010 through increasing sales of Company's newer enzymes including Fuelzyme® alpha-amylase, Xylathin™ xylanase, Veretase® alpha-amylase, Deltazym® GA L-E5 glucoamylase and Purifine® PLC;
  • Signed a lease agreement for new office and laboratory space in the Torrey Pines area of San Diego, which is targeted to commence in 2012 following the completion of construction and tenant improvements;
  • Ended the quarter with unrestricted cash and cash equivalents totaling $44.6 million and convertible notes outstanding of $44.2 million; and
  • Subsequent to the end of the second quarter, repurchased $8.2 million in principal amount of outstanding convertible notes.

  • Financial ResultsIn the commentary below, the historical results of the Company's ligno-cellulosic biofuels business for current and prior periods have been reclassified into discontinued operations as a result of the sale of the ligno-cellulosic biofuels business on September 2, 2010 to BP Biofuels North America LLC.

    Revenues

    Revenues for the periods ended June 30, 2011 and 2010 were as follows (in thousands):Three Months Ended June 30,Six Months Ended June 30,2011201020112010Revenues:Animal Health and Nutrition

    $
    8,035$
    8,887$
    ,110$
    ,841Grain Processing

    4,5353,1528,4296,239All other products

    1,9081,2512,9711,772Total product

    14,47813,29027,51024,852Collaborative

    6563901,0201,052Total revenues

    $
    5,134$
    3,680$
    28,530$
    25,904Total revenues for the six months ended June 30, 2011 increased 10% to $28.5 million from $25.9 million for the same period in the prior year, with product revenues representing approximately 96% of total revenues in both periods. Product revenues for the six months ended June 30, 2011 increased 11% to $27.5 million from $24.9 million for the same period in the prior year, primarily due to an increase in revenues from grain processing enzymes, including Fuelzyme® alpha-amylase, Veretase® alpha-amylase, Deltazym® GA L-E5 glucoamylase and Xylathin™ xylanase. These products continued to gain traction in the grain ethanol markets and together with Purifine® PLC for soybean oil processing, achieved significant revenue growth over 2010.

    Product Gross Profit and Gross Margin

    Product gross profit for the six months ended June 30, 2011 increased 6% to $10.0 million from $9.5 million for the same period in prior year. Gross margin decreased to 36% of product revenue for the six months ended June 30, 2011, compared to 38% for the six months ended June 30, 2010.  Gross margin decreased primarily due to a decrease in the royalty paid as profit share from sales of Phyzyme phytase by our partner Danisco Animal Nutrition.

    Operating Expenses (excluding cost of product revenue and restructuring expense)

    Excluding cost of product revenues and restructuring, total operating expenses related to continuing operations for the six months ended June 30, 2011 decreased to $14.1 million (including share-based compensation of $0.3 million) from $16.3 million (including share-based compensation of $0.6 million) for the same period in the prior year; this is  primarily due to reimbursement of legal fees of $1.1 million for expenses incurred during 2010 for defense of the Company's noteholder lawsuit which was settled on March 23, 2011, and to initiatives to decrease general and administrative expenses. As a partial offset, research and development costs for continued investment in pipeline products showed an increase.

    Restructuring Expense

    On March 31, 2011 the Company closed its office in Cambridge, Massachusetts, resulting in a charge of $2.9 million, consisting of employee termination costs, facilities closure costs, and employee relocation costs for several employees who were relocated to San Diego.

    Operating Loss from Continuing Operations

    Operating loss from continuing operations for the six months ended June 30, 2011 was $6.0 million compared to $5.7 million for the same period in 2010. This increase is primarily reflective of restructuring expenses of $2.9 million. Excluding the impact of restructuring, operating loss from continuing operations decreased $2.7 million, primarily due to the reimbursement of legal fees and further reductions in general and administrative expenses.

    Net Income (loss) from Continuing Operations

    Net income from continuing operations for the six months ended June 30, 2011 was $2.3 million compared to a net loss of $9.9 million for the same period in 2010, on a GAAP accounting basis. Adjusted for the impact of non-cash items related to the Company's convertible debt, the Company's non-GAAP pro-forma net loss from continuing operations for the six months ended June 30, 2011 was $7.7 million compared to $9.8 million for the same period in the prior year. The Company believes that excluding the impact of these items provides a more consistent measure of operating results.  

    Balance Sheet

    The Company ended the second quarter of 2011 with $44.6 million in cash and cash equivalents, $5.0 million in restricted cash, and $44.2 million in debt at face value. Subsequent to the end of the second quarter, on July 27, 2011, the Company repurchased $8.2 million in principal amount of its outstanding convertible notes in a privately negotiated transaction. To effect this repurchase, the Company paid a total of $7.7 million in cash to a noteholder to retire principal, plus $0.2 million of accrued interest as of the closing date, leaving the Company with approximately $36 million in face value of debt at that date.

    "We are encouraged by the strong operational and financial performance achieved in the first half of the year," said Jeffrey Black, Senior Vice President and Chief Financial Officer.  "Our ability to increase product revenues and product gross profit, while at the same time lowering operating expenses and conserving cash, signifies that we are executing on our strategy to strengthen our balance sheet and position the Company for future growth."

    About VereniumVerenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

    Forward-Looking StatementsStatements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets and future financial performance, results and objectives, all of which are prospective.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, risks associated with Verenium's technologies, risks associated with Verenium's ability to obtain additional capital to support its planned operations and financial obligations, risks associated with Verenium's dependence on patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements, and its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2010 and any updates contained in its subsequently filed quarterly reports on Form 10-Q.  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.

    Contacts:Kelly Lindenboom

    Vice President, Corporate Communications

    858-431-8580

    kelly.lindenboom@verenium.com

    Sarah Carmody

    Manager, Corporate Communications

    858-431-8581

    sarah.carmody@verenium.comVerenium CorporationConsolidated Statements of Operations(unaudited, in thousands, except per share amounts)Three Months Ended June 30, Six Months Ended June 30,2011201020112010Revenues:Product

    $
    4,478$
    3,290$
    27,510$  24,852Collaborative

    6563901,0201,052Total revenue

    15,13413,68028,53025,904Operating expenses:Cost of product revenue

    9,3928,83017,47615,346Product gross profit

    5,0864,46010,0349,506Product gross margin

    35%34%36%38%Research and development

    2,2881,2494,9202,676Selling, general and administrative

    4,6666,4959,16613,582Restructuring charges

    82--2,920--Total operating expenses

    16,42816,57434,48231,604Operating loss from continuing operations

    (1,294)(2,894)(5,952)(5,700)Other income and expense:Interest and other expense, net

    (692)(2,127)(1,753)(4,107)Gain on debt extinguishment upon conversion of convertible notes

    ------598Gain on debt extinguishment upon repurchase of convertible notes

    ----11,284--Gain (loss) on net change in fair value of derivative assets and liabilities

    518(786)(1,295)(718)Total other income (expense), net

    (174)(2,913)8,236(4,227)Income (loss) from continuing operations

    (1,468)(5,807)2,284(9,927)Discontinued operations:Income (loss) from discontinued operations

    --(6,353)61(21,729)Less: Loss attributed to noncontrolling interests in

    consolidated entities – discontinued operations

    --7,675--15,175Net income (loss) attributed to Verenium

    $
    (1,468)$   (4,485)$
    2,345$   (16,481)Basic and diluted net income (loss) per share:

    Continuing operations

    $
    (0.12)$
    (0.47)$
    .18$
    (0.82)Discontinued operations

    $
    --$
    (0.52)$
    --$
    (1.79)Net income (loss)

    $
    (0.12)$
    (0.37)$
    .19$
    (1.35)Shares used in computing basic and diluted net income (loss) per share

    12,60612,27312,60612,165Verenium CorporationCondensed Consolidated Balance Sheet Data(unaudited, in thousands)June 30,December 31,20112010Cash and cash equivalents

    $
    44,620$
    87,929Restricted cash, short term

    5,000--Accounts receivable, net

    9,4476,708Inventory, net

    5,6495,316Other current assets  

    2,5082,694Restricted cash, long term

    --5,000Property and equipment, net  

    3,6453,134Other noncurrent assets  

    602976Total assets  

    $
    71,471$
    ,757Current liabilities, excluding deferred revenue, restructuring and liabilities of discontinued operations

    $
    ,703$
    ,849Deferred revenue, current  

    3,499894Accrued restructuring, current

    1,047--Convertible notes, at carrying value (face value of $44.2 million at June 30, 2011 and $74.7 million at December 31, 2010)

    48,24288,011Other long term liabilities  

    9461,216Liabilities of discontinued operations  

    6831,617Stockholders' equity  

    6,3513,170Total liabilities and

    stockholders' equity  

    $
    71,471$
    ,757Verenium CorporationUnaudited Supplemental and Non-GAAP Pro Forma Financial Information(in thousands, except per share amounts)The following unaudited supplemental and non-GAAP pro forma financial information is derived from the Company's condensed consolidated financial statements for the three and six months periods ended June 30, 2011 and 2010, as reported under GAAP. The Company believes that such supplemental and non-GAAP financial information is helpful to understand the results of operations of the business. Non-GAAP Pro Forma Net Loss From Continuing OperationsThree Months Ended
    June 30,Six Months Ended
    June 30,2011201020112010Income (loss) from continuing operations

    $
    (1,468)$
    (5,807)$
    2,284$
    (9,927)Adjustments:  Gain on debt extinguishment upon repurchase of convertible notes

    ----(11,284)--Gain on debt extinguishment upon conversion of convertible notes

    ------(598)(Gain) loss on net change in fair value of derivative assets and liabilities

    (518)7861,295718Non-GAAP pro forma net loss from continuing operations  

    $
    (1,986)$
    (5,021)$
    (7,705)$
    (9,807)Non-GAAP pro forma net loss from continuing operations per share  

    $
    (0.16)$
    (0.41)$
    (0.61)$
    (0.81)
    '/>"/>

    SOURCE Verenium Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
    2. Verenium Corporation to Present at the William Blair & Company 2008 Small-Cap Growth Stock Conference
    3. Verenium Corporation to Announce Third Quarter 2008 Financial Results
    4. Verenium Corporation to Speak at the Credit Suisse Alternative Energy Conference
    5. Verenium Regains Compliance With Nasdaq Continued Listing Requirement
    6. Verenium Announces First Commercial Cellulosic Ethanol Project
    7. Verenium Announces Organizational Changes
    8. Verenium Completes Amendment to 8% Senior Convertible Notes
    9. BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol
    10. Verenium Announces Reverse Stock Split to Take Effect September 9
    11. Verenium 1:12 Reverse Stock Split Takes Effect
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/8/2016)... 2016 AskLinkerReports.com has published a report ... Amyloglucosidase Industry 2016 Market Research Report. From a basic outline ... overview are all covered in the report. This report projects ... analysis of the Amyloglucosidase industry. ... , , ...
    (Date:12/8/2016)... Dec. 8, 2016  Renova™ Therapeutics, a biotechnology ... failure and type 2 diabetes, announced that it ... adeno-associated virus (AAV) vector developed in the laboratory ... at Stanford University. The company plans to use ... therapy product pipeline. "Early research ...
    (Date:12/8/2016)... ... December 08, 2016 , ... The ability ... optogenetics — is key to exciting advances in the study and mapping of ... projected via free-space optics stimulates small, transparent organisms and excites neurons within superficial ...
    (Date:12/8/2016)... England , December 8, 2016 ... das Unternehmen für Molekulargenetik, erweitert seine Palette an ... myPanel™ NGS Custom FH Panels, das ein schnelles ... (FH) ermöglicht. Das Panel bietet eine Erkennung von ... Variations (CNV) mit einem einzigen kleinen Panel und ...
    Breaking Biology Technology:
    (Date:11/30/2016)... Nov. 30, 2016 Not many of us realize that we spend ? ... so we need to do it well. Inadequate sleep levels have been found to ... stroke, diabetes, and even cancer. Maybe now is the best time to ... help them to manage their sleep quality? Continue Reading ... ...
    (Date:11/29/2016)... 29, 2016 Nearly one billion matches per second ... ... DERMALOG is Germany's ... efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification ...
    (Date:11/22/2016)... , Nov. 22, 2016   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... Medical LiveWire Healthcare and Life Sciences Awards as ... caps off an unprecedented year of recognition and growth ... for over 15 years. iMedNet ...
    Breaking Biology News(10 mins):